TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
NCT04599790
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG:
TACE combined with lenvatinib and sintilimab
Sponsor
Second Affiliated Hospital of Guangzhou Medical University